Court Finds Corcept Therapeutics’ Patents Not Infringed
02 Janeiro 2024 - 10:00AM
Corcept Therapeutics Incorporated (NASDAQ: CORT), a
commercial-stage company engaged in the discovery and development
of medications to treat severe endocrine, oncology, metabolism, and
neurology disorders by modulating the effects of the hormone
cortisol, today announced the Court for the District of New Jersey
issued a decision that Teva Pharmaceuticals does not infringe any
asserted claims of Corcept’s U.S. Patents 10,195,214 and
10,842,800, both of which concern methods of safely administering
Korlym® with drugs that are strong CYP3A4 inhibitors.
“This disappointing decision is based on legal
and factual errors we are confident will be reversed on appeal,”
said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer.
“Our patents describe medical discoveries that have greatly
expanded the therapeutic options available to patients suffering
from Cushing’s syndrome, which is why the FDA added them to
Korlym’s prescribing instructions. Doctors have followed these
instructions and will continue to do so to safely treat patients.
Failure to recognize the novelty and import of discoveries like
these would fundamentally change the law, to the detriment of the
many patients whom innovative companies seek to serve.”
“We will pursue our appeal vigorously,” added
Dr. Belanoff, “and will continue to assert our intellectual
property rights whenever they are infringed.”
About Corcept Therapeutics
For more than 25 years, Corcept’s focus on
cortisol modulation and its potential to treat patients across a
wide variety of serious disorders has led to the discovery of more
than 1,000 proprietary selective cortisol modulators. Corcept’s
advanced clinical trials are being conducted in patients with
hypercortisolism, solid tumors, amyotrophic lateral sclerosis (ALS)
and liver disease (NASH). In February 2012, the company introduced
Korlym, the first medication approved by the U.S. Food and Drug
Administration for the treatment of patients with Cushing’s
syndrome. Corcept is headquartered in Menlo Park, California. For
more information, visit Corcept.com.
Forward-Looking Statements
Statements in this press release, other than
statements of historical fact, are forward-looking statements based
on our current plans and expectations that are subject to risks and
uncertainties that might cause our actual results to differ
materially from those such statements express or imply. These risks
and uncertainties include, but are not limited to, those related to
Korlym, including its clinical attributes, regulatory approvals,
mandates, oversight and other requirements; the practices of
physicians in prescribing Korlym, either as monotherapy or in
combination with other drugs, the scope and protective power of our
intellectual property and the outcome of any current or future
legal proceedings, including our appeal of the Court’s decision in
our litigation with Teva Pharmaceuticals. These and other risks are
set forth in our SEC filings, which are available at our website
and the SEC’s website. We disclaim any intention or duty to update
forward-looking statements made in this press release.
CONTACTInvestor
inquiries:ir@corcept.comMedia
inquiries:CorceptCommunications@corcept.comwww.corcept.com
Corcept Therapeutics (NASDAQ:CORT)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Corcept Therapeutics (NASDAQ:CORT)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024